Procoralan

Land: Den Europæiske Union

Sprog: engelsk

Kilde: EMA (European Medicines Agency)

Køb det nu

Indlægsseddel Indlægsseddel (PIL)
12-10-2021
Produktets egenskaber Produktets egenskaber (SPC)
12-10-2021

Aktiv bestanddel:

ivabradine hydrochloride

Tilgængelig fra:

Les Laboratoires Servier

ATC-kode:

C01EB17

INN (International Name):

ivabradine

Terapeutisk gruppe:

Cardiac therapy

Terapeutisk område:

Angina Pectoris; Heart Failure

Terapeutiske indikationer:

Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated :in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Produkt oversigt:

Revision: 22

Autorisation status:

Authorised

Autorisation dato:

2005-10-25

Indlægsseddel

                                28
B. PACKAGE LEAFLET
29
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
PROCORALAN 5
MG FILM-COATED TABLETS
PROCORALAN 7.5
MG FILM-COATED TABLETS
ivabradine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Procoralan is and what it is used for
2.
What you need to know before you take Procoralan
3.
How to take Procoralan
4.
Possible side effects
5
How to store Procoralan
6.
Contents of the pack and other information
1.
WHAT PROCORALAN IS AND WHAT IT IS USED FOR
Procoralan (ivabradine) is a heart medicine used to treat:
-
Symptomatic stable angina pectoris (which causes chest pain) in adult
patients whose heart rate is
over or equal to 70 beats per minute. It is used in adult patients who
do not tolerate or cannot take
heart medicines called beta-blockers. It is also used in combination
with beta-blockers in adult
patients whose condition is not fully controlled with a beta-blocker.
-
Chronic heart failure in adult patients whose heart rate is over or
equal to 75 beats per minute. It is
used in combination with standard therapy, including beta-blocker
therapy or when beta-blockers
are contraindicated or not tolerated.
About stable angina pectoris (usually referred to as “angina”):
Stable angina is a heart disease which happens when the heart does not
receive enough oxygen. The
most common symptom of angina is chest pain or discomfort.
About chronic heart failure :
Chronic heart failure is a heart disease which happens when your heart
cannot pump enough blood to
the rest of your body. The most c
                                
                                Læs hele dokumentet
                                
                            

Produktets egenskaber

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Procoralan 5 mg film-coated tablets
Procoralan 7.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Procoralan 5 mg film-coated tablets
Each film-coated tablet contains 5 mg ivabradine (as hydrochloride).
_Excipient with known effect: _
Each film-coated tablet contains 63.91 mg lactose monohydrate.
Procoralan 7.5 mg film-coated tablets
Each film-coated tablet contains 7.5 mg ivabradine (as hydrochloride).
_Excipient with known effect: _
Each film-coated tablet contains 61.215 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Procoralan 5 mg film-coated tablets
Salmon-coloured, oblong, film-coated tablet scored on both sides,
engraved with “5” on one face
and
on the other face.
The tablet can be divided into equal doses.
Procoralan 7.5 mg film-coated tablets
Salmon-coloured, triangular, film-coated tablet engraved with
“7.5” on one face and
on the other
face.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Symptomatic treatment of chronic stable angina pectoris
Ivabradine is indicated for the symptomatic treatment of chronic
stable angina pectoris in coronary
artery disease adults with normal sinus rhythm and heart rate ≥ 70
bpm. Ivabradine is indicated:
-
in adults unable to tolerate or with a contraindication to the use of
beta-blockers
-
or in combination with beta-blockers in patients inadequately
controlled with an optimal beta-
blocker dose.
3
Treatment of chronic heart failure
Ivabradine is indicated in chronic heart failure NYHA II to IV class
with systolic dysfunction, in adult
patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in
combination with standard therapy
including beta-blocker therapy or when beta-blocker therapy is
contraindicated or not tolerated (see
section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Symptomatic treatment of chronic stable angina pectoris _
It is recommended that the deci
                                
                                Læs hele dokumentet
                                
                            

Dokumenter på andre sprog

Indlægsseddel Indlægsseddel bulgarsk 12-10-2021
Produktets egenskaber Produktets egenskaber bulgarsk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport bulgarsk 26-02-2019
Indlægsseddel Indlægsseddel spansk 12-10-2021
Produktets egenskaber Produktets egenskaber spansk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport spansk 26-02-2019
Indlægsseddel Indlægsseddel tjekkisk 12-10-2021
Produktets egenskaber Produktets egenskaber tjekkisk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport tjekkisk 26-02-2019
Indlægsseddel Indlægsseddel dansk 12-10-2021
Produktets egenskaber Produktets egenskaber dansk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport dansk 26-02-2019
Indlægsseddel Indlægsseddel tysk 12-10-2021
Produktets egenskaber Produktets egenskaber tysk 12-10-2021
Indlægsseddel Indlægsseddel estisk 12-10-2021
Produktets egenskaber Produktets egenskaber estisk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport estisk 26-02-2019
Indlægsseddel Indlægsseddel græsk 12-10-2021
Produktets egenskaber Produktets egenskaber græsk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport græsk 26-02-2019
Indlægsseddel Indlægsseddel fransk 12-10-2021
Produktets egenskaber Produktets egenskaber fransk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport fransk 26-02-2019
Indlægsseddel Indlægsseddel italiensk 12-10-2021
Produktets egenskaber Produktets egenskaber italiensk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport italiensk 26-02-2019
Indlægsseddel Indlægsseddel lettisk 12-10-2021
Produktets egenskaber Produktets egenskaber lettisk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport lettisk 26-02-2019
Indlægsseddel Indlægsseddel litauisk 12-10-2021
Produktets egenskaber Produktets egenskaber litauisk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport litauisk 26-02-2019
Indlægsseddel Indlægsseddel ungarsk 12-10-2021
Produktets egenskaber Produktets egenskaber ungarsk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport ungarsk 26-02-2019
Indlægsseddel Indlægsseddel maltesisk 12-10-2021
Produktets egenskaber Produktets egenskaber maltesisk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport maltesisk 26-02-2019
Indlægsseddel Indlægsseddel hollandsk 12-10-2021
Produktets egenskaber Produktets egenskaber hollandsk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport hollandsk 26-02-2019
Indlægsseddel Indlægsseddel polsk 12-10-2021
Produktets egenskaber Produktets egenskaber polsk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport polsk 26-02-2019
Indlægsseddel Indlægsseddel portugisisk 12-10-2021
Produktets egenskaber Produktets egenskaber portugisisk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport portugisisk 26-02-2019
Indlægsseddel Indlægsseddel rumænsk 12-10-2021
Produktets egenskaber Produktets egenskaber rumænsk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport rumænsk 26-02-2019
Indlægsseddel Indlægsseddel slovakisk 12-10-2021
Produktets egenskaber Produktets egenskaber slovakisk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport slovakisk 26-02-2019
Indlægsseddel Indlægsseddel slovensk 12-10-2021
Produktets egenskaber Produktets egenskaber slovensk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport slovensk 26-02-2019
Indlægsseddel Indlægsseddel finsk 12-10-2021
Produktets egenskaber Produktets egenskaber finsk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport finsk 26-02-2019
Indlægsseddel Indlægsseddel svensk 12-10-2021
Produktets egenskaber Produktets egenskaber svensk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport svensk 26-02-2019
Indlægsseddel Indlægsseddel norsk 12-10-2021
Produktets egenskaber Produktets egenskaber norsk 12-10-2021
Indlægsseddel Indlægsseddel islandsk 12-10-2021
Produktets egenskaber Produktets egenskaber islandsk 12-10-2021
Indlægsseddel Indlægsseddel kroatisk 12-10-2021
Produktets egenskaber Produktets egenskaber kroatisk 12-10-2021
Offentlige vurderingsrapport Offentlige vurderingsrapport kroatisk 26-02-2019

Søg underretninger relateret til dette produkt